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INTRODUCTION AND OBJECTIVES: Objective: To compare the surgical, oncological, and functional outcomes of laparoscopic and percutaneous cryoablation for the treatment of small renal masses.
METHODS: A systematic review of the literature was performed through March 2016 using PubMed, Scopus, and Ovid databases. Article selection proceeded according to the search strategy based on PRISMA criteria. Only studies comparing laparoscopic and percutaneous kidney cryoablation were included in the meta-analysis.
RESULTS: Eleven studies were selected for the analysis including 1725 cases: 804 (46.6%) percutaneous and 921 (53.4%) laparoscopic cryoablation. Included studies were all retrospective comparative ones. Percutaneous cryoablation was performed more frequently for posterior tumors (p<0.001), whereas laparoscopy was more common for endophytic lesions (p¼0.01). The length of follow-up was longer for laparoscopy (p<0.001). Percutaneous cryoablation was associated with a significantly shorter hospital stay (p<0.001). A lower likelihood of residual disease was recorded for laparoscopic (p¼0.003), whereas tumor recurrence rate favored percutaneous cryoablation (p¼0.02). The two procedures were similar for recurrence free survival (p¼ 0.08), and overall survival (p¼0.51). No significant difference was found in post-operative eGFR (p¼0.78).
CONCLUSIONS: Laparoscopic and percutaneous kidney cryoablation offer similar favorable oncological outcomes with minimal impact on renal function. The percutaneous access can offer shorter hospital stay and faster recovery, which can be appealing in an era of cost restraint. Determining which approach to use in clinical practice will depend on the available technology and specific expertise at each center.
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MP100-20 CRYOTHERAPY AND THERMAL ABLATION FOR RENAL MALIGNANCY OVER 3 CENTIMETERS -COMPARATIVE ANALYSIS OF SURVIVAL WITH SMALL RENAL MASSES
Alex Jones*, Megan Dinino, Mark Wakefield, Katie Murray, Naveen Pokala, Columbia, MO INTRODUCTION AND OBJECTIVES: Ablative treatments achieve good oncological outcome for renal parenchymal tumors 3 centimeters (cm) or smaller. Larger renal malignancies are increasingly being treated with ablation. This comparative study determines the survival following ablation in these large renal masses.
METHODS: Patients undergoing cryotherapy or thermal ablation (Procedure codes 13, 15, or 23) for renal tumors were identified from the Surveillance, Epidemiology, and End Result (SEER) Database from 1998-2013. Exclusion criteria included T stage not recorded, more than one primary malignancy, metastatic disease, or node positive disease. Demographics, stage, and overall (OS) and cancer specific survival (CSS) were analyzed. T1a tumors were compared to T1b or T2 tumors. Tumors 3 cm or less were compared to greater than 3 cm.
RESULTS: A total of 4,886 patients were identified, and 2,340 patients met inclusion criteria. The mean age was 66.5 years, 1,943 were white, 243 were black, and 1,419 were male. The stage distribution included T1a (n¼2159), T1b (n¼172), and T2 (n¼9). 1,186 tumors were right-sided, 1,149 were left-sided, and the remaining were bilateral or not specified. 2,326 patients had the size recorded. 1,637 patients had 3 cm or smaller tumors and 689 tumors were larger than 3 cm. The OS in T1a tumors was 84.4% at 5 years and 69.2% at 9 years. In individuals with T1b tumors, OS was 62% at 5 years and 38% at 9 years. The T2 tumors had an OS of 64.8% at 57 months. The 5 year CSS was 97.4% in the whole group, 97.9% in T1a, and 97.4% in the T1b group. The corresponding 9 year CSS was 96.9, 97.5, and 96.9%. Comparative CSS in patients with T1a tumors was 98% at 5 years and 97.5% at 9 years. In T1b or greater tumors, the 5 and 9 year survival was 90.2%. All patients that survived beyond 5 years were alive at 9 years of followup. On analysis by size, tumors 3 cm or less had a 98.4 5-yr and a 98.2 9-yr CSS and tumors that were greater than 3 cm had 95% 5-yr and a 93.9 9-yr survival. On univariate analysis, both T1a tumors and tumors smaller than 3 cm had significantly better survival (p¼0.001).
CONCLUSIONS: Ablative therapies for small renal masses can achieve excellent CSS at 97% at 9 years. This study demonstrates that reasonable CSS can be achieved in masses larger than 3 cm and patients with T1b or larger tumors. Further studies are required to address the role of ablative therapies for larger renal masses.
